Psychedelics Report | Psychedelic Research, News & Explainers
In focus
The Psychedelic Treatment Package: Preparation, Support and Follow-Up
Psychedelics Report Editorial Team · October 30, 2026
Read story1 / 5
News & insights
Insight
Psilocybin for Alcohol Use Disorder: What the Heavy-Drinking Outcome Means
By Psychedelics Report Editorial Team · October 30, 2026
News
Primary Outcomes in Psychedelic Trials: Why One Positive Measure Is Not the Whole Result
By Psychedelics Report Editorial Team
News
Psychedelic Trials and Masking: Why Expectations Complicate the Comparison
By Psychedelics Report Editorial Team
News
Microdosing and Expectations: What a Self-Blinding Study Can Establish
By Psychedelics Report Editorial Team
News
The Psychedelic Treatment Package: Preparation, Support and Follow-Up
By Psychedelics Report Editorial Team
News
How to Read a Psychedelic Treatment Trial: A Guide to Evidence and Uncertainty
By Psychedelics Report Editorial Team
News
Psilocybin Therapy: What Patients Should Know About the Evidence
By Psychedelics Report Editorial Team
Editor's picks
Selected story
The Psychedelic Treatment Package: Preparation, Support and Follow-Up
October 30, 2026
Selected story
How to Read a Psychedelic Treatment Trial: A Guide to Evidence and Uncertainty
October 30, 2026
Selected story
Psilocybin Therapy: What Patients Should Know About the Evidence
October 29, 2026
Selected story
MDMA-Assisted Therapy for PTSD: Understanding the Treatment Model
October 29, 2026
Latest headlines
The big picture
How Long Do Psychedelic Benefits Last? Reading Follow-Up Without a Permanent-Reset Claim
October 30, 2026
Read the full storyLatest News
How Long Do Psychedelic Benefits Last? Reading Follow-Up Without a Permanent-Reset Claim
October 30, 2026
Psychedelic Brain Imaging: Desynchronization Is Not Proof of Antidepressant Benefit
October 30, 2026
Cancer-Related Distress and Psilocybin: Symptom Relief Is Not Cancer Treatment
October 30, 2026
Psilocybin and Smoking Cessation: Why a Pilot Study Is Not a Quit-Rate Promise
October 30, 2026
Psilocybin for Alcohol Use Disorder: What the Heavy-Drinking Outcome Means
October 30, 2026
Primary Outcomes in Psychedelic Trials: Why One Positive Measure Is Not the Whole Result
October 30, 2026
Psychedelic Trials and Masking: Why Expectations Complicate the Comparison
October 30, 2026
Microdosing and Expectations: What a Self-Blinding Study Can Establish
October 30, 2026
Psychedelic Safety: Why Screening and Follow-Up Matter
October 29, 2026
How to Evaluate a Psychedelic Clinical Trial Before Volunteering
October 29, 2026
Psilocybin Depression Trial Found Improvement, but Follow-Up Was Short
October 29, 2026
MDMA Phase 3 PTSD Trial: Positive Results With Important Caveats
October 29, 2026
Ketamine Met a Noninferiority Benchmark Against ECT in a Depression Trial
October 29, 2026
LSD-Derived MM120 Reduced Anxiety in a Phase 2b Study
October 29, 2026
Psilocybin Safety Review Found More Acute Side Effects Than Comparators
October 29, 2026